Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Manno, 2007, A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study, Am J Kidney Dis, 49, 763, 10.1053/j.ajkd.2007.03.013
Berthoux, 2008, Natural history of primary IgA nephropathy, Semin Nephrol, 28, 4, 10.1016/j.semnephrol.2007.10.001
Moriyama, 2014, Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan, PLoS One, 9, e91756, 10.1371/journal.pone.0091756
Reich, 2007, Remission of proteinuria improves prognosis in IgA nephropathy, J Am Soc Nephrol, 18, 3177, 10.1681/ASN.2007050526
Zhang, 2015, Immunoglobulin A nephropathy: current progress and future directions, Transl Res, 166, 134, 10.1016/j.trsl.2015.02.007
2012, KDIGO Guidelines: Chapter 10: Immunoglobulin A nephropathy, Kidney Int Suppl, 2, 209, 10.1038/kisup.2012.23
Lv, 2009, Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial, Am J Kidney Dis, 53, 26, 10.1053/j.ajkd.2008.07.029
Manno, 2009, Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy, Nephrol Dial Transplant, 24, 3694, 10.1093/ndt/gfp356
Pozzi, 2004, Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial, J Am Soc Nephrol, 15, 157, 10.1097/01.ASN.0000103869.08096.4F
Rauen, 2015, Intensive supportive care plus immunosuppression in IgA nephropathy, N Engl J Med, 373, 2225, 10.1056/NEJMoa1415463
Kiryluk, 2014, Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens, Nat Genet, 46, 1187, 10.1038/ng.3118
Smith, 2006, O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy, J Am Soc Nephrol, 17, 3520, 10.1681/ASN.2006060658
Suzuki, 2011, The pathophysiology of IgA nephropathy, J Am Soc Nephrol, 22, 1795, 10.1681/ASN.2011050464
Tomana, 1999, Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies, J Clin Invest, 104, 73, 10.1172/JCI5535
Yeo, 2015, Emerging therapies in immunoglobulin A nephropathy, Nephrology (Carlton), 20, 788, 10.1111/nep.12527
Edsbäcker, 1993, Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules, Gastroenterology, 104, A695
Smerud, 2011, New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria, Nephrol Dial Transplant, 26, 3237, 10.1093/ndt/gfr052
Le, 2012, Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population, Nephrol Dial Transplant, 27, 1479, 10.1093/ndt/gfr527
Watts, 2005, TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract, Expert Opin Drug Deliv, 2, 159, 10.1517/17425247.2.1.159
Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006
Praga, 2003, Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial, J Am Soc Nephrol, 14, 1578, 10.1097/01.ASN.0000068460.37369.DC
Tang, 2010, Long-term study of mycophenolate mofetil treatment in IgA nephropathy, Kidney Int, 77, 543, 10.1038/ki.2009.499
Inker, 2016, Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis, Am J Kidney Dis, 10.1053/j.ajkd.2016.02.042
Lambers Heerspink, 2014, GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials, Am J Kidney Dis, 64, 860, 10.1053/j.ajkd.2014.08.018
Woo, 2009, Beneficial effects of high-dose losartan in IgA nephritis, Clin Nephrol, 71, 617, 10.5414/CNP71617
Floege, 2011, Current therapy for IgA nephropathy, J Am Soc Nephrol, 22, 1785, 10.1681/ASN.2011030221
Lv
Vivante, 2013, Hematuria and risk for end-stage kidney disease, Curr Opin Nephrol Hypertens, 22, 325, 10.1097/MNH.0b013e32835f7241
Moreno, 2016, Haematuria as a risk factor for chronic kidney disease progression in glomerular diseases: a review, Pediatr Nephrol, 31, 523, 10.1007/s00467-015-3119-1
Lv, 2012, Corticosteroid therapy in IgA nephropathy, J Am Soc Nephrol, 23, 1108, 10.1681/ASN.2011111112
Nam, 2014, Optimal proteinuria target for renoprotection in patients with IgA nephropathy, PLoS One, 9, e101935, 10.1371/journal.pone.0101935
Edsbäcker, 2004, Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease, Clin Pharmacokinet, 43, 803